IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.

Andrea Markkula, Maria Simonsson, Christian Ingvar, Carsten Rose, Helena Jernström

Research output: Contribution to journalArticlepeer-review

16 Citations (SciVal)
161 Downloads (Pure)

Abstract

In breast cancer, high levels of the inflammatory cytokine interleukin-6 (IL-6) have been associated with disease-free survival and treatment resistance. Increased serum levels of IL-6 have been correlated with increased levels of NF-κβ and aromatase expression in adipose tissue. Several IL6 single nucleotide polymorphisms have been associated with breast cancer prognosis, but the impact may differ depending on tumour oestrogen receptor (ER) status. This translational study investigated the association between IL6 genotypes, ER-status, and treatment on the risk of early events among breast cancer patients.
Original languageEnglish
Article number759
JournalBMC Cancer
Volume14
DOIs
Publication statusPublished - 2014

Subject classification (UKÄ)

  • Cancer and Oncology

Fingerprint

Dive into the research topics of 'IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.'. Together they form a unique fingerprint.

Cite this